Published in Genetics and Environmental Business Week, November 30th, 2006
Under the agreement, terms of which have not been disclosed, Avecia will carry out development work to optimize the drug manufacturing process and conduct initial cGMP manufacture of IB657 in Avecia's ABC1000 biologics facility in the Tees Valley, U.K. This manufacturing agreement will provide Illumigen with IB657 in sufficient quantities to complete phase Ia clinical trials in Hepatitis C-infected...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.